Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies', we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies', only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Project leader: Dr Maxime Taquet, Academic Clinical Fellow

During his ACF, Maxime has mostly focused on the combined use of large-scale electronic health records data to characterise the neurological and psychiatric sequelae of COVID-19.

In a first paper, Maxime and his colleagues showed a bidirectional link between COVID-19 and psychiatric disorders. In a second, they characterised the risk of neurological and psychiatric disorders in the 6 months after a diagnosis of COVID-19. In a third paper, they used similar techniques to explore the risk of long-COVID signs and symptoms after COVID-19 compared to influenza. In a fourth paper, they further characterised the neurological and psychiatric risk trajectories in the 2 years following a diagnosis of COVID-19.

In other papers, they investigated:

  • whether the risk of neurological and psychiatric sequelae differ in those with prior vaccination,
  • whether the risk of eating disorders has changed during the pandemic,
  • whether exposure to specific drugs affects the risk of post-COVID brain fog,
  • whether people with COVID-19 are at an increased risk of epilepsy and seizures, and
  • whether exposure to lithium affects the risk of COVID-19.

Reaching the end of his ACF, Maxime is now combining large-scale electronic health records data with prospectively collected data and biomarkers. This is to better understand what the mechanisms behind post-COVID neuropsychiatric sequelae might be.     


February 2023